INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
1. Pomerantz LLP investigates Gilead for potential securities fraud. 2. FDA placed clinical hold on HIV treatment trials GS-1720 and GS-4182. 3. Gilead's stock fell 2.58% after the FDA announcement. 4. Investors can join a class action regarding Gilead's practices. 5. Safety signals in trials raised concerns about product efficacy.